Chelsea Therapeutics International (CHTP) announced after the bell Tuesday that the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 16-1 to recommend approval of NORTHERA, for the treatment of symptomatic neurogenic orthostatic hypotension.
Chelsea Therapeutics gapped open sharply higher Wednesday, but gave back some of its early gains over the course of the trading session. Shares finished with a gain of 2.11 at $4.41 on the highest volume of the year. The stock closed challenging the highs of the year, trading at a week and a half high.
by RTT Staff Writer
For comments and feedback: email@example.com